Washington. Healthcare. Translated.


Health Reform: The Future for Drug (Non-)Price (Non-)Controls?

There’s more brewing in US health reform than ever. Is this good or bad for the world of pharma?   ...
Read More

Departing FDA Commissioners: Do Their Initiatives Continue?

Several clients have asked what Commissioner Gottlieb’s departure will mean – to their own industries and other FDA constituencies. To ...
Read More

Pipeline Drugs: Another Victim of Rx Price Reforms

The drug pipeline is filled with high-priced, high-impact cures. Drug price reforms might kill them – is there any cure ...
Read More

Opioids: PS on drugmaker liability

I recently posted some thoughts on the dilemma drugmakers face in balancing their reporting obligations to FDA against their general ...
Read More